Necrolytic Migratory Erythema-like Eruption Associated with Erlotinib in a Patient with Lung Adenocarcinoma

Erlotinib is a tyrosine kinase inhibitor commonly used in patients with lung cancer. While cutaneous manifestations may develop after the use of erlotinib, including acneiform eruption, paronychia, and xerosis, erlotinib-related necrolytic migratory erythema (NME)-like skin eruptions have not been reported [1]. Here, we described a rare case of NME-like skin eruption that developed in a patient with lung cancer treated with erlotinib.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research